Zacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Quarterly Sales of $2.62 Million
Analysts forecast that Kala Pharmaceuticals Inc (NASDAQ:KALA) will report sales of $2.62 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Kala Pharmaceuticals’ earnings. The highest sales estimate is $3.25 million and the lowest is $2.00 million. The business is scheduled to report its next earnings report on Thursday, August 8th.
On average, analysts expect that Kala Pharmaceuticals will report full-year sales of $13.66 million for the current year, with estimates ranging from $7.00 million to $20.00 million. For the next financial year, analysts anticipate that the firm will report sales of $75.11 million, with estimates ranging from $38.90 million to $110.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Thursday, May 9th. The company reported ($0.75) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.75). The firm had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.96 million.
Shares of KALA traded up $0.06 during midday trading on Wednesday, reaching $5.94. 232,401 shares of the stock were exchanged, compared to its average volume of 212,185. Kala Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $17.33. The company has a debt-to-equity ratio of 0.67, a quick ratio of 10.17 and a current ratio of 10.41. The company has a market capitalization of $201.27 million, a P/E ratio of -2.40 and a beta of 1.64.
A number of hedge funds have recently bought and sold shares of KALA. RA Capital Management LLC raised its stake in Kala Pharmaceuticals by 114.7% in the fourth quarter. RA Capital Management LLC now owns 4,537,478 shares of the company’s stock valued at $22,188,000 after purchasing an additional 2,424,242 shares in the last quarter. Athyrium Capital Management LP acquired a new position in Kala Pharmaceuticals in the fourth quarter valued at about $6,520,000. Sofinnova Investments Inc. raised its stake in Kala Pharmaceuticals by 365.8% in the fourth quarter. Sofinnova Investments Inc. now owns 445,516 shares of the company’s stock valued at $2,178,000 after purchasing an additional 349,861 shares in the last quarter. BlackRock Inc. raised its stake in Kala Pharmaceuticals by 29.2% in the fourth quarter. BlackRock Inc. now owns 1,427,672 shares of the company’s stock valued at $6,980,000 after purchasing an additional 322,311 shares in the last quarter. Finally, Fosun International Ltd acquired a new position in Kala Pharmaceuticals in the fourth quarter valued at about $1,208,000. 67.92% of the stock is owned by institutional investors and hedge funds.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
See Also: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.